611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Only Select Incidental Thyroid Nodules Need Further EvaluationTravelers Bring Malaria Back to U.S., With High CostsThe Top 5 Conditions That Shorten Americans' Lives -- And Are PreventableHealth Tip: Dealing With Foot ArthritisCDC: Salmonella Infection Prevalence Down in 2016Do Diet Sodas Pose Health Risks?Hantavirus Pulmonary Syndrome Risk Up for Some PopulationsHealth Tip: When Asthma Doesn't ImproveHealth Tip: Help Manage ConstipationChagas Disease Presents Public Health Challenge in the U.S.FDA Approves Device to Help Curb Cluster HeadachesReview: Interventions Don't Promote Exercise in Rural AdultsDiffering Statin Guidelines Leave Many Clinicians UncertainIllness From 'Kissing Bug' Now Widespread in U.S.Conflicting Statin Guidelines Leave Millions in 'Gray Zone'No Link Between Common Antibiotic, Irregular HeartbeatEpilepsy: Another Potential Zika Threat to BabiesUveitis Risk Higher Among Individuals With PsoriasisOne in Five Post-Op Patients Need Unscheduled HelpNew Bowel Disorder Treatments Needed, FDA SaysWhat's the Best Seasonal Allergy Med for Your Kid?Another Type of Mosquito May Carry ZikaCould a Daily Vitamin Curb Smog's Effect on the Heart?Accurate Diagnosis of Endocrine Hypertension ImportantKidney Disease a Big Contributor to Heart-Related Deaths: StudyOverweight, Underweight Both Tied to MigrainesDon't Let Ticks Get Under Your SkinSpecific Factors Influence First-Line Biologic Rx for PsoriasisA Healthier Weight May Mean Fewer MigrainesDiabetes Continues Its Relentless Rise1st Drug for Tardive Dyskinesia ApprovedHealth Tip: When to Worry About Neck PainChemicals Found in Many U.S. Streams: StudyAHA: Patients Lack Confidence in Managing Their CholesterolAsymptomatic C. difficile Ups Risk for Other Hospital PatientsSilk Clothes Won't Soothe Eczema's ItchHealth Tip: Recognizing Symptoms of Lactose IntoleranceHealth Tip: Should You Be Tested for Kidney Disease?Many Americans Don't Know How to Handle High CholesterolBotox May Help Ease 'Burning Mouth' SyndromeInsulin Resistance Predicts Later Cognitive DeclineMusic Therapy Relieves Post-Op Pain in Spinal Surgery PatientsLower Risk of Gastrointestinal Bleeding for ApixabanBedbugs Building Resistance to More InsecticidesObesity May Make Rheumatoid Arthritis Tough to Spot, TrackXanax, Valium May Boost Pneumonia Risk in Alzheimer's PatientsU.S. Blood Banks Can Protect Blood Supply From Zika VirusHow to Protect Yourself From Air PollutionIntestinal Reovirus Infection May Be Cause of Celiac DiseaseFDA Approves Hep C Drugs for Kids 12 and Older
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Lower Risk of Gastrointestinal Bleeding for Apixaban


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, according to a study published in the April issue of Gastroenterology.

Neena S. Abraham, M.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues conducted a retrospective study using administrative claims data of privately insured individuals and Medicare Advantage enrollees. Three propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban were created. Data were compared on rivaroxaban versus dabigatran for 31,574 patients; for apixaban versus dabigatran for 13,084 patients; and for apixaban versus rivaroxaban for 13,130 patients.

The researchers found that GI bleeding occurred more often in patients given rivaroxaban versus dabigatran (hazard ratio, 1.2). The risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban (hazard ratios, 0.39 and 0.33, respectively). For apixaban and rivaroxaban, the median times to gastrointestinal bleeding were <90 days, while for dabigatran, the median time was <120 days.

"In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile " the authors write.

Abstract
Full Text
Editorial